Dr. Chen's research discovered that myeloma tumors produce a protein, pleiotrophin, that assists tumor growth by a completely novel mechanism in which a type of white cell called a monocyte turns into a new blood vessel. This discovery has opened exciting new avenues in the development of treatment for myeloma patients and the paper has been published in the prestigious Blood (Chen H. et al. 1; 110: 287-95, 2007).
Dr. Chen has also developed innovative siRNA technology that has led to new advances in controlling the growth of myeloma tumors in the bone as well as stemming the loss of bone density. The paper, Interference with nuclear factor kappa B and c-Jun NH2-terminal kinase signaling by TRAF6C small interfering RNA inhibits myeloma cell proliferation and enhances apoptosis has been published in Oncogene (Chen H. et al. 25; 6520-7, 2006) He continues to design new uses for this technology to target anti-myeloma therapies to specific genes.
Furthermore, Dr. Chen led the discovery of a novel platelet binding protein that allowed advancements in research for new therapies for multiple myeloma and lymphoma. For more information, visit www.imbcr.org
